Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines
18. April 2022 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines Both studies fully recruited, with data from the Dengue Fever...
Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives
14. April 2022 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives Emergex’s CD8+ T cell Adaptive Vaccine...
Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate
07. April 2022 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate Abingdon, Oxon, UK, 7 April 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or...
Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus
22. Februar 2022 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus Abingdon, Oxon, UK, 22 February...
Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations
30. November 2021 08:51 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations Emergex confirms that...
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
15. November 2021 07:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...
Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate
15. November 2021 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate Synthetic vaccine designed to prime T-Cells to rapidly remove...
Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine
30. Juni 2021 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine Swiss regulatory authorities, including the Swiss Agency for Therapeutic...
Emergex Strengthens Senior Management Team
23. Februar 2021 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Strengthens Senior Management Team Appointments of Mr Robin Cohen as Business Development Director and Ms Susi Osborne as Manufacturing Director Abingdon, Oxon,...
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
05. Januar 2021 07:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical...